Devices & Diagnostics

Haemonetics hopes to stanch red ink with $578M blood management deals

Massachusetts-based Haemonetics Corp. announced Sunday that it will buy St. Paul, Minnesota-based Hemerus Medical for up to $27 million. It will pay another $551 million to acquire certain blood filtration and processing assets of Pall Corp. The payment to Hemerus will occur in stages and is contingent upon Hemerus meeting regulatory success with its patented […]

Massachusetts-based Haemonetics Corp. announced Sunday that it will buy St. Paul, Minnesota-based Hemerus Medical for up to $27 million. It will pay another $551 million to acquire certain blood filtration and processing assets of Pall Corp.

The payment to Hemerus will occur in stages and is contingent upon Hemerus meeting regulatory success with its patented whole blood collection system, SOLX. The goal for Haemonetics is to get a slice of the global manual whole blood collection market, which its CEO Brian Concannon described as a $1.2 billion market. And with it a return to profitability that has eluded the Massachusetts company recently.

Hemerus, which developed the SOLX system through partial funding from the U.S. Army, has filed a new drug application with the U.S. Food and Drug Administration. The company believes that its blood collection and storage system is superior to current systems for managing blood because it can extend the quality and effective life of red blood cells, according to a news release. The company expects FDA approval sometime this year.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

The acquisition will boost Haemonetics effort to enter the whole blood collection market.

While the Hemerus acquisition is small, Haemonetics is shelling out a whopping $551 million to acquire the blood collection, filtration and processing product lines of Pall Corp., based in Port Washington, New York.

Haemonetics is betting big on these two acquisitions and needs them to be successful. In the quarter ended March 31, the company’s net income declined 15.2 percent to $17.8 million compared with $21 million a year ago. Earnings per diluted share fell to 69 cents from 81 cents. Including the fourth quarter it reported Monday, Haemonetics has lost money in four successive quarters.

 

 

Arundhati Parmar is VP and Editor-in-Chief at MedCity News. In this role, she oversees MedCity's news coverage as well as develops the content for several conferences that the publication hosts. Previously, she was Senior Editor at UBM's Medical Device + Diagnostic Industry. Arundhati has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again. Contact her at [email protected]>.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.